Milestone Pharmaceuticals Inc.

Quick facts

Phase 3 pipeline

• Etripamil NS · Cardiovascular
  Etripamil is a rapid-onset, short-acting calcium channel blocker administered as a nasal spray that slows heart rate and reduces blood pressure by blocking L-type calcium channels in cardiac and vascular tissue.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Milestone Pharmaceuticals Inc. portfolio CI brief
• Milestone Pharmaceuticals Inc. pipeline updates RSS